

## (E) -Daporinad

**Catalog No: tcsc1055**



### Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg



### Specifications

---

**CAS No:**

658084-64-1

**Formula:**

$C_{24}H_{29}N_3O_2$

**Pathway:**

Metabolic Enzyme/Protease;Autophagy

**Target:**

Nampt;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 50$  mg/mL (127.71 mM)

**Alternative Names:**

FK866;APO866

**Observed Molecular Weight:**

391.51


**Product Description**

FK866 is an effective inhibitor of nicotinamide phosphoribosyltransferase (**NMPRTase**) with an **IC<sub>50</sub>** of 0.09 nM.

IC50 & Target: IC50: 0.09 nM (NMPRTase)

**In Vitro:** Nampt inhibition with FK866 induces significant NAD<sup>+</sup> intracellular reduction and selectively kills MM cells. FK866-induced cell death is associated with inhibition of Nampt activity, rather than protein expression, and higher NAD<sup>+</sup> baseline levels in MM cells than normal PBMCs confer FK866 sensitivity. FK866 abrogates the survival advantage conferred by the bone marrow microenvironment<sup>[1]</sup>. FK866 prevents the [Ca<sup>2+</sup>]<sub>i</sub> increase induced by different mitogens and reduces the Ca<sup>2+</sup> content of TG-responsive Ca<sup>2+</sup> stores in Jurkat and in activated PBLs. FK866 reduces the Ca<sup>2+</sup> content of TG-responsive Ca<sup>2+</sup> stores in Jurkat cells but not in Bcl2-Jurkat cells<sup>[2]</sup>. Inhibition of NAMPT by FK866, or inhibition of SIRT by nicotinamide decreases proliferation and triggered death of 293T cells involving the p53 acetylation pathway<sup>[3]</sup>.

**In Vivo:** FK866 (30 mg/kg, i.p.) decreases the tumor burden in CB17-SCID mice, and the tumor tissue demonstrates a significant decrease in ERK phosphorylation and proteolytic cleavage of LC3<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!